Kaplan-Meier estimates of the rates of the primary end-point (all-cause death, or major CV events) at two years were 26.3% in the pravastatin group and 22.4% in the atorvastatin group, reflecting a 16% reduction in the hazard ratio in favor of atorvastatin (p=0.005). The study thus identified the superiority of the more intensive atorvastatin regimen.

1. Cannon CP, Braunwald E, et al. N Engl J Med 2004; 350(15): 1495-1504